1. Home
  2. TYRA vs WD Comparison

TYRA vs WD Comparison

Compare TYRA & WD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

N/A

Current Price

$22.30

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Logo Walker & Dunlop Inc

WD

Walker & Dunlop Inc

N/A

Current Price

$41.42

Market Cap

1.2B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
TYRA
WD
Founded
2018
1937
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2021
2010

Fundamental Metrics

Financial Performance
Metric
TYRA
WD
Price
$22.30
$41.42
Analyst Decision
Strong Buy
Buy
Analyst Count
15
4
Target Price
$47.45
★ $49.33
AVG Volume (30 Days)
★ 563.7K
529.6K
Earning Date
11-20-2026
11-05-2026
Dividend Yield
N/A
★ 6.96%
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $1,234,306,000.00
Revenue This Year
N/A
$7.05
Revenue Next Year
N/A
$9.53
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 8.99
52 Week Low
$13.83
$31.40
52 Week High
$40.65
$69.19

Technical Indicators

Market Signals
Indicator
TYRA
WD
Relative Strength Index (RSI) 57.49 69.46
Support Level $18.46 $39.01
Resistance Level $22.37 $43.13
Average True Range (ATR) 1.04 1.64
MACD 0.27 0.98
Stochastic Oscillator 76.27 96.91

Price Performance

Historical Comparison
TYRA
WD

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About WD Walker & Dunlop Inc

Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of its total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.

Share on Social Networks: